GenXone SA
+ business areaBioPharma R&D+Services
2019 – 205,000 PLN
2020 – 20,474,000 PLN
2021 – 23,195,000 PLN
2022 – 10,587,000 PLN
2023 – 2,394,000 PLN
2024 – 1,788,000 PLN
2020 – 22
2021 – 22
2022 – 24
2023 – 20
2024 – 16
2019 – 50,000 PLN
2020 – 168,000 PLN
2021 – 1,168,000 PLN
2022 – 1,545,000 PLN
2023 – 1,353,000 PLN
2024 – 1,354,000 PLN
GenXone is a Polish biotechnology company that offers nucleic acid (DNA and RNA) sequencing services based on nanopore sequencing technology. It is one of 32 companies worldwide licensed for commercial use of the technology developed by Oxford Nanopore Technologies. The company creates its own solutions, including laboratory protocols and bioinformatics tools, to enable the use of nanopore sequencing in various fields, such as genetic diagnostics, food industry, veterinary medicine, and agriculture. Since March 2020, GenXone has been highly involved in the fight against COVID-19, focusing on SARS-CoV-2 genome sequencing.